Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors PR Newswire JERUSALEM, Feb. 24, 2014 JERUSALEM, Feb. 24, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage...
Paine & Partners Forms New Advisory Relationship With SDA Ventures LLC Will Work with SDA Principals Steve Dubin and David Abramson to Identify and Execute Investment Opportunities in the Human...
Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame Martek One of Only Eight Companies Inducted into the Inaugural SBIR Hall of Fame PR Newswire COLUMBIA, Md...
Standard & Poor's Announces Changes to U.S. Index PR Newswire NEW YORK, Feb. 14, 2011 NEW YORK, Feb. 14, 2011 /PRNewswire/ -- S&P will make the following changes to SmallCap 600...
Egleston Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Martek Biosciences Corporation (NASDAQ:...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Martek Biosciences Corporation (NASDAQ:...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Martek Biosciences Corporation (“Martek” or the “Company”...
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/matk) is investigating potential claims against the board of directors of Martek Biosciences Corp. ("Martek" or the "Company...
The Law Office of Joseph Klein is investigating the Board of Directors of Martek Biosciences Corporation (“Martek”) (NasdaqGS: MATK) for possible breaches of fiduciary duty and...
Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
